PVLA announces QTORIN pitavastatin; investor call and exhibits

Rhea-AI Filing Summary

Palvella Therapeutics (PVLA) announced a new product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis (DSAP). The company is hosting an investor call on November 5, 2025 at 8:30 a.m. Eastern Time, with materials available via a webcast link.

An investor presentation was furnished as Exhibit 99.1 and a press release as Exhibit 99.2. The information was furnished under Item 7.01 and is not deemed filed under the Exchange Act.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001583648 0001583648 2025-11-05 2025-11-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

PALVELLA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-37471	30-0784346
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

353 W. Lancaster Avenue, Suite 200
Wayne, Pennsylvania	19087
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On November 5, 2025, Palvella Therapeutics, Inc. (the “Company”) will host a conference call with investors at 8:30 a.m. Eastern Time, to present a new product candidate for the Company. The live event and accompanying slides can be accessed by visiting https://edge.media-server.com/mmc/p/juyi9nm8/.  A copy of the investor presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference.

The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On November 5, 2025, the Company also issued a press release announcing a new product candidate, QTORIN™ pitavastatin, for the treatment of disseminated superficial actinic porokeratosis (“DSAP”). A copy of the press release is furnished herewith as Exhibit 99.2, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Document
99.1		Corporate Presentation on QTORIN™ Pitavastatin dated November 5, 2025*
99.2		Press Release issued by Palvella Therapeutics, Inc. on November 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PALVELLA THERAPEUTICS, INC.
Date: November 5, 2025	By:	/s/ Matthew Korenberg
		Matthew Korenberg
		Chief Financial Officer

FAQ

What did Palvella Therapeutics (PVLA) disclose in this 8-K?

The company announced a new product candidate, QTORIN™ pitavastatin, for DSAP, and provided related investor materials.

When is PVLA’s investor call and how can it be accessed?

The call is on November 5, 2025 at 8:30 a.m. ET, with a webcast link provided in the materials.

Which exhibits accompany the PVLA 8-K?

Exhibit 99.1: Corporate presentation on QTORIN™ pitavastatin; Exhibit 99.2: Press release announcing the product candidate.

What is the indication for QTORIN™ pitavastatin?

It is described for the treatment of disseminated superficial actinic porokeratosis (DSAP).

Is the information considered filed or furnished?

It was furnished under Item 7.01 and is not deemed filed under the Exchange Act.

Where is PVLA listed and what is its ticker?

Palvella Therapeutics trades on The Nasdaq Capital Market under the ticker PVLA.